Amy VandenBerg

Amy VandenBerg has over 20 years of experience in the regulatory and clinical affairs field. Amy began their career in 1998 at Cygnus, Inc. as a Clinical Trials Manager. The following year, they became a Clinical Research Associate at Cygnus, Inc. In 2003, they joined DexCom, Inc. as a Clinical & Regulatory Affairs Associate. Amy was later promoted to Manager of Regulatory and then Director of Regulatory Affairs. From 2008 to 2020, they held various positions at Obalon Therapeutics, including Sr. Director of Regulatory Affairs, Vice President Regulatory & Clinical Affairs, Chief Clinical & Regulatory Officer, and Chief Officer of Quality Assurance, Clinical Affairs & Regulatory Affairs. In 2020, they joined Curative Inc. as Sr. Vice President Regulatory Affairs/Quality/Clinical. Most recently, they were appointed Vice President Regulatory Affairs at Biolinq in 2021.

Amy VandenBerg attended Saint Mary's College of California from 1994 to 1998, where they earned a degree in Biology with a focus on Systemic Physiology, Genetics, Immunology, Economics, and Spanish. Prior to that, they attended College Park High School.